Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab in pediatric relapsing multiple sclerosis
2025-522257-19-00Phase 3Authorised
- Sponsor
- TG Therapeutics, Inc.
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of ublituximab in multiple sclerosis (MS) (3 arms), sponsored by TG Therapeutics, Inc. Primary endpoints: Safety and CD19+ B-cell response. Planned start May 2026; status: authorised.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2025-522257-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522257-19-00.